Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
471.44
+3.85 (+0.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
Got $500? 3 Pharma Stocks to Buy and Hold Forever
May 26, 2024
These players might even beat the market when the conditions are right.
Via
The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
May 26, 2024
Shares of the growing biotech company have doubled in three years.
Via
The Motley Fool
2 Biotech Stocks to Buy in May
May 25, 2024
You could buy these in any month, really.
Via
The Motley Fool
3 High-Flying Stocks That Could Soar Even More
May 25, 2024
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.
Via
The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
May 23, 2024
Via
Benzinga
SLB, First Solar And 2 Other Stocks Insiders Are Selling
May 23, 2024
Via
Benzinga
Should you consider NASDAQ:VRTX for quality investing?
May 22, 2024
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Exhibits Quality Stock Traits. Here's Why.
Via
Chartmill
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
May 15, 2024
Via
Benzinga
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
May 08, 2024
Via
Benzinga
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
May 23, 2024
Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents.
Via
Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
May 23, 2024
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy.
Via
InvestorPlace
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
May 16, 2024
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.
Via
Investor's Business Daily
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
May 15, 2024
How much would you pay for a stock that might earn $25 a year in six years?
Via
The Motley Fool
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
May 15, 2024
Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform.
Via
Benzinga
Exposures
COVID-19
Smart Money Is Betting Big In VRTX Options
May 06, 2024
Via
Benzinga
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
3 Cheap Biotech Stocks to Buy Now: May 2024
May 14, 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.
Via
InvestorPlace
Exposures
Product Safety
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
May 14, 2024
Via
Benzinga
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
May 12, 2024
The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors.
Via
The Motley Fool
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade
May 12, 2024
These companies are raking in profits at astonishing clips.
Via
The Motley Fool
Stock Market Moves Toward Highs; Arista, Toast, Palantir Key Earnings Movers: Weekly Review
May 10, 2024
Big earnings winners and losers continued.
Via
Investor's Business Daily
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
May 08, 2024
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable.
Via
Chartmill
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
May 08, 2024
New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
Markets In A Minute - "A Lack Of Further Progress"
May 07, 2024
May's FOMC meeting left the Fed Funds Rate unchanged. JOLTS showed fewer job openings with increased layoffs. April's job report disappointed, adding only 175k jobs and seeing higher unemployment....
Via
Talk Markets
Topics
Economy
Workforce
Exposures
Interest Rates
Layoff
10 Health Care Stocks With Whale Alerts In Today's Session
May 07, 2024
Via
Benzinga
US Stocks Eye Fourth Positive Session Despite Hawkish Fed Remarks; Disney, Palantir Tumble; Treasury Yields Fall: What's Driving Markets Tuesday?
May 07, 2024
Wall Street experienced a quiet session during morning trading on Tuesday, influenced by a lack of significant economic data and minimal updates on earnings from major large-cap companies.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
VRTX Stock Earnings: Vertex Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 06, 2024
VRTX stock results show that Vertex Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
May 06, 2024
VRTX earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook
May 06, 2024
Vertex Pharmaceuticals beat first-quarter sales and earnings forecasts.
Via
Investor's Business Daily
3 Biotech Stocks to Double Your Money in the Next 24 Months
May 06, 2024
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.